Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors (Q46578424)

23 December 2017

title

Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors (English)

1 reference

23 December 2017

author name string

Kozo Yoshikawa

1 reference

23 December 2017

Mitsuo Shimada

1 reference

23 December 2017

Nobuhiro Kurita

1 reference

23 December 2017

Hirohiko Sato

1 reference

23 December 2017

Takashi Iwata

1 reference

23 December 2017

Shinya Morimoto

1 reference

23 December 2017

Tomohiko Miyatani

1 reference

23 December 2017

Hideya Kashihara

1 reference

23 December 2017

Chie Takasu

1 reference

23 December 2017

Noriko Matsumoto

1 reference

23 December 2017

publication date

11 November 2012

1 reference

23 December 2017

published in

Surgery Today

1 reference

23 December 2017

volume

1 reference

23 December 2017

issue

1 reference

23 December 2017

page(s)

1162-1167

1 reference

23 December 2017

18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Is FDG-PET/CT useful for managing malignant pleural mesothelioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

FDG-PET/CT findings of autoimmune pancreatitis associated with idiopathic retroperitoneal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

FDG-PET/CT for cancer management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Multidetector CT of high-risk patients with occult gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Staging non-small cell lung cancer by whole-body positron emission tomographic imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Role of F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-012-0411-6

Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: report of a case

21 January 2018

1 reference

12 December 2020

Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver

1 reference

12 December 2020

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

12 December 2020

The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.

1 reference

12 December 2020

Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT.

1 reference

12 December 2020

Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients

1 reference

12 December 2020

10.1007/S00595-012-0411-6

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017